Vesigen Therapeutics, Inc.

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable extracellular vesicle delivery technology.

[Vesigen Therapeutics, Inc. @Vesigen]

We are pleased to share that Turn Biotechnologies has acquired Vesigen's ARMMs technology
https://t.co/R9m7Tv3YLE

[Vesigen Therapeutics, Inc. @Vesigen]

We are excited to be participating in Canaccord Genuity’s 44th Annual Growth Conference, hosted in Boston! Tomorrow, August 14th, our CEO, Paulash Mohsen, will be presenting at 11:30 AM EST.

[Vesigen Therapeutics, Inc. @Vesigen]

We're hosting a blood drive at our office on Tuesday July 16th from 9:00-2:30! There are plenty of spots available and it's open to the public. We're located at 790 Memorial Drive in Cambridge, MA. Help us give back to the community by signing up here: https://t.co/ZN7W7BLXue

[Vesigen Therapeutics, Inc. @Vesigen]

Just one more day until our CSO, Joe Nabhan, will be speaking about our engineered #ARMMs platform at the Next Generation Gene Therapy Vectors Summit in Boston!

[Vesigen Therapeutics, Inc. @Vesigen]

That's a wrap on our time at #ARVO2024 and #ASGCT2024! Check out our press release at the link below for a recap of what was presented last week.
https://t.co/xf8Q9VjVJg

[Vesigen Therapeutics, Inc. @Vesigen]

Join us for our final presentations of #ASGCT2024 at 12:00 PM today!

[Vesigen Therapeutics, Inc. @Vesigen]

Interested in learning about #ARMMs? Check out one (or all!) of @Vesigen's posters today at #ASGCT2024

[Vesigen Therapeutics, Inc. @Vesigen]

@Vesigen is back at it with another poster presentation at #ARVO2024 today from 2:15-4:00PM!

[Vesigen Therapeutics, Inc. @Vesigen]

Check out @Vesigen at #ASGCT2024 today!

[Vesigen Therapeutics, Inc. @Vesigen]

Today is the first of Vesigen Therapeutics, Inc.'s two presentations at #ARVO2024. Stop by the Exhibit Hall from 3:00-4:45 PM!

[Vesigen Therapeutics, Inc. @Vesigen]

We're excited to be presenting new preclinical data at the 2024 ARVO Annual Meeting on May 6th and May 8th. Check out our latest press release for more information including the details of our presentations.

#ARVO2024 #ARMMs

https://t.co/LF0GR9xkKx

[Vesigen Therapeutics, Inc. @Vesigen]

If you're attending the Exosome Characterization & Analytical Development Summit in Boston today, don't miss out on Kristin's presentation!

[Vesigen Therapeutics, Inc. @Vesigen]

@Vesigen will be at #ASGCT2024 presenting exciting new preclinical data on our engineered #ARMMs technology! Check out our press release for more information including the details of our 10 poster presentations May 8-10.
https://t.co/ZvxFp2xNRz

[Vesigen Therapeutics, Inc. @Vesigen]

@Vesigen CEO, Paulash Mohsen, will be presenting at the 2024 Cell and Gene Meeting on the Med in Rome, Italy this week! Tune in virtually or in person on Wednesday April 10th at 10:45 AM CET. https://t.co/AVUGFFz2oS

[Vesigen Therapeutics, Inc. @Vesigen]

Today is #RareDiseaseDay, a day dedicated to raising awareness and generating change for the 300 million people worldwide living with a rare disease. @Vesigen's technology aims to make a positive change in the lives of rare disease patients through novel transformative therapies

[Vesigen Therapeutics, Inc. @Vesigen]

Check out our latest press release about being announced as a Phase 1 winner in The National Institutes of Health's TARGETED Challenge! 

https://t.co/hpZ8E31bpR

[Vesigen Therapeutics, Inc. @Vesigen]

Our proposal "Engineered ARMMs: Promising Human-Derived Vectors for Cell Type-Specific Delivery of Genome Editors" was selected as a winning solution for programmable delivery systems for gene editing in the @NIH TARGETED Challenge! #genomeediting #ARMMs

https://t.co/mTXkzDNJdF

[Vesigen Therapeutics, Inc. @Vesigen]

Check out our latest press release to learn what we've been up to this week in Brussels at #ESGCT2023
https://t.co/LxaJF5mZsN

[Vesigen Therapeutics, Inc. @Vesigen]

Tune in to hear CSO, Joe Nabhan, tomorrow October 26th at 11:00 AM & 11:00 PM EST! #TakingBOLDAction
https://t.co/HSPPHN2Lak

[Vesigen Therapeutics, Inc. @Vesigen]

Check out our latest press release to learn about the potential of our non-viral #ARMMs technology!

https://t.co/2fdngetPC9